BiotechTube
Neumirna

Neumirna

Copenhagen, Denmark· Est.
neumirna.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Total funding raised: $4.2M

Overview

Neumirna is a private, pre-revenue biotech pioneering a novel miRNA-targeting platform for neurological disorders. Its lead asset, NMT.001, is a clinical-stage candidate for drug-resistant epilepsy, with a preclinical program in Parkinson's disease. Backed by leading European life science investors and founded by experts in neuroscience and RNA biology, the company is positioned to advance a new class of therapeutics that address significant unmet medical needs in neurology.

NeurologyEpilepsyParkinson's Disease

Technology Platform

MicroRNA (miRNA)-targeting oligonucleotide platform designed to modulate gene expression networks and restore healthy neural function in neurological diseases.

Funding History

1
Total raised:$4.2M
Seed$4.2M

Opportunities

The significant unmet need in drug-resistant epilepsy and the lack of disease-modifying therapies for Parkinson's present large, addressable markets.
Success with its lead program could validate the miRNA platform, enabling expansion into other neurological and potentially non-neurological indications.

Risk Factors

Key risks include the clinical and biological uncertainty of miRNA modulation in the brain, the challenge of effective CNS delivery for oligonucleotides, and dependence on future fundraising as a pre-revenue company.
Failure of the lead asset would jeopardize the entire platform.

Competitive Landscape

Competition includes other RNA-targeting biotechs (e.g., using ASOs, siRNA) in neurology, as well as large pharma companies pursuing novel mechanisms for epilepsy and Parkinson's. Neumirna's specific focus on miRNA networks is a differentiating but unproven approach.

More companies in RNA Therapeutics (non-mRNA) →More companies in Denmark →